Welcome to our dedicated page for Johnson & Johnson SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson’s vast reach—spanning immunology breakthroughs, orthopedic implants, and everyday consumer staples—makes its SEC disclosures a gold mine of insight and a maze of technical detail. Drug-trial readouts, device recall costs, talc litigation updates, and dividend policy changes are scattered across hundreds of pages, prompting searches like “Johnson & Johnson SEC filings explained simply” and “Johnson & Johnson insider trading Form 4 transactions.”
Stock Titan’s AI decodes every document the moment it hits EDGAR. Whether you need the Johnson & Johnson quarterly earnings report 10-Q filing for segment revenue trends, a Johnson & Johnson annual report 10-K simplified view of risk factors, or a quick alert on Johnson & Johnson Form 4 insider transactions real-time, our platform extracts what matters. Key forms are mapped to practical insights:
- 10-K & 10-Q: pipeline progress, consumer health margins, R&D spend—ready for instant Johnson & Johnson earnings report filing analysis
- 8-K: product recalls and courtroom milestones with Johnson & Johnson 8-K material events explained
- Form 4: track Johnson & Johnson executive stock transactions Form 4 before market moves
- DEF 14A: explore Johnson & Johnson proxy statement executive compensation alongside peer benchmarks
Busy analysts, portfolio managers, and healthcare specialists use our AI summaries to cut reading time, monitor compliance events, and compare quarter-over-quarter performance. By understanding Johnson & Johnson SEC documents with AI, you can spot safety signals, verify dividend coverage, and gauge insider confidence—without sifting through 300-page PDFs. Real-time feeds, historical archives, and plain-language explanations ensure you never miss a disclosure that could shift your investment thesis.
Form 144 notice for Johnson & Johnson (JNJ) reports a proposed sale of 9,570 shares of Common stock through Fidelity Brokerage Services with an aggregate market value of $1,695,805.91, to be sold approximately on 08/29/2025 on the NYSE. The filing lists total shares outstanding as 2,408,338,872.
The filer indicates the shares were acquired via an option (granted 02/13/2017) and the acquisition and payment date is recorded as 08/29/2025 with payment in cash. No other securities were reported sold in the past three months and the form contains the standard certification regarding lack of undisclosed material information.
Joaquin Duato, CEO and Chairman of Johnson & Johnson (JNJ), reported transactions on Form 4 dated 08/22/2025 showing the exercise and sale of company shares. On 08/22/2025 he exercised 125,824 employee stock options at an exercise price of $101.87 per share, and contemporaneously sold 125,824 shares at a weighted average sale price of $179.2079. After these transactions the filing shows 275,967 shares beneficially owned directly. The report also discloses 401,791 shares held directly following another acquisition entry and 130,852 shares held indirectly by spouse and 974 shares indirectly via a 401(k) plan as of the plan reporting date.
The Form 4 was signed by an attorney-in-fact on 08/25/2025 and includes an explanation that the sale prices reflect multiple trades between $178.985 and $179.37 and that dividend reinvestment figures are as of 07/31/2025. The filing documents a routine insider option exercise and sale rather than disclosure of new compensation terms.
Johnson & Johnson (JNJ) filed a Form 144 reporting a proposed sale of 125,824 common shares through Fidelity Brokerage Services with an aggregate market value of $22,652,723.84. The filing states the shares are to be sold on or about 08/22/2025 and that the shares were acquired via an option granted on 02/08/2016, with payment to be cash at sale.
The filer certifies there is no undisclosed material information and indicates no other securities of the issuer were sold by the same person in the past three months. The disclosure documents a sizable, rule-compliant planned insider sale routed through a broker on the NYSE.
Joseph J. Wolk, Executive Vice President and Chief Financial Officer of Johnson & Johnson (JNJ), reported transactions dated 08/15/2025. He exercised 16,820 employee stock options at an exercise price of $101.87 and simultaneously sold 16,820 common shares at a weighted-average sale price of $176.9067 (trades ranged $176.87–$177.015). After these transactions his direct beneficial ownership is reported as 14,000 shares. He also holds 68,835 shares indirectly via a spousal lifetime access trust (SLAT) and 2,145 shares indirectly through the Johnson & Johnson 401(k) stock fund. The form was signed by an attorney-in-fact on 08/18/2025.
Form 144 notice for Johnson & Johnson (JNJ): The filing reports a proposed sale of 16,820 shares of common stock through Fidelity Brokerage Services LLC on the NYSE with an approximate sale date of 08/15/2025. The filing lists an aggregate market value of $2,975,571.23 for the shares and shows 2,408,338,872 shares outstanding. The securities were acquired under options granted on 02/08/2016, the purchaser is listed as the issuer, and the indicated form of payment is cash. The filer certifies they have no undisclosed material adverse information.
FAQ
What is the current stock price of Johnson & Johnson (JNJ)?
What is the market cap of Johnson & Johnson (JNJ)?
